Dave Nellesen

Dave Nellesen


M.B.A., Haas School of Business, University of California, Berkeley; Ph.D., molecular biology, University of California, San Diego; B.S., biochemistry, University of California, Los Angeles

Summary of Experience

Dr. Nellesen specializes in consulting on and applying a range of strategies that address client needs in the development and commercialization of products in the biotechnology, pharmaceutical, molecular diagnostic, and medical device industries. He is an expert in value proposition and evidence strategy, helping clients to develop clinical and economic evidence of value to support launch strategy and secure favorable reimbursement. This work often includes published or unpublished evidence of the value of new products, including evidence dossiers (global value dossiers or AMCP dossiers) and related payer communication tools, health economic models, and peer-reviewed studies. Dr. Nellesen also assists clients in conducting primary research with payers and other stakeholders to assess the value of new technologies and the evidence needed for favorable market access. Prior to joining Analysis Group, Mr. Nellesen spent more than 15 years working directly in the biopharmaceutical industry, where he led a range of commercial strategy engagements, including strategic planning, intellectual property management and valuation, health care compliance, and business process improvement. Among other experience, he has worked as a consultant at PRTM and as a scientist and patent portfolio manager at Incyte Pharmaceuticals.